Insulin Icodec-Abae has 21 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Albuterol, Alcohol, Clonidine. Patients taking Insulin Icodec-Abae should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 21
- Moderate
- 21
Moderate (21)
- Insulin Icodec-Abae + Albuterol— May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.
- Insulin Icodec-Abae + Alcohol— May increase or decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required…
- Insulin Icodec-Abae + Clonidine— May increase or decrease blood glucose lowering effect and blunt signs/symptoms of hypoglycemia. Dose adjustment and inc…
- Insulin Icodec-Abae + Clozapine— May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.
- Insulin Icodec-Abae + Danazol— May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.
- Insulin Icodec-Abae + Disopyramide— May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
- Insulin Icodec-Abae + Epinephrine— May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.
- Insulin Icodec-Abae + Fluoxetine— May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
- Insulin Icodec-Abae + Glucagon— May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.
- Insulin Icodec-Abae + Guanethidine— May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring required.
- Insulin Icodec-Abae + Isoniazid— May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.
- Insulin Icodec-Abae + Lithium— May increase or decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required…
- Insulin Icodec-Abae + Niacin— May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.
- Insulin Icodec-Abae + Octreotide— May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
- Insulin Icodec-Abae + Olanzapine— May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.
- Insulin Icodec-Abae + Pentamidine— May cause hypoglycemia followed sometimes by hyperglycemia. Dose adjustment and increased glucose monitoring required.
- Insulin Icodec-Abae + Pentoxifylline— May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
- Insulin Icodec-Abae + Pramlintide— May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
- Insulin Icodec-Abae + Reserpine— May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring required.
- Insulin Icodec-Abae + Somatropin— May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.
- Insulin Icodec-Abae + Terbutaline— May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.